Antioxidant N-acetylcysteine protects pancreatic β-cells against aldosterone-induced oxidative stress and apoptosis in female db/db mice and insulin-producing MIN6 cells

Endocrinology

Volumn 154, Issue 11, 2013, Pages 4068-4077

  Jin, Hui Min ^a   Zhou, Dong Chi ^a   Gu, Hui Fang ^a   Qiao, Qing Yan ^a   Fu, Shun Kun ^a   Liu, Xiao Li ^b   Pan, Yu ^b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALDOSTERONE; CASPASE 3; MINERALOCORTICOID RECEPTOR; POTASSIUM ION; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P22; PROTEIN P67; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SODIUM ION;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL VIABILITY; CONTROLLED STUDY; DIET RESTRICTION; ENZYME ACTIVITY; FEMALE; GLUCOSE METABOLISM; HORMONE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ACETYLCYSTEINE; ALDOSTERONE; ANIMALS; APOPTOSIS; BLOOD GLUCOSE; BODY WEIGHT; CELL LINE; FEMALE; INSULIN; INSULIN-SECRETING CELLS; MICE; MICE, INBRED NOD; NADPH OXIDASE; OXIDATIVE STRESS; POTASSIUM; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SODIUM;

EID: 84886483694     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1115     Document Type: Article

References (38)

1. Viengchareun S, Le Menuet D, Martinerie L, Munier M, Pascual-Le Tallec L, Lombès M. The mineralocorticoid receptor: insights into its molecular and (patho) physiological biology. Nucl Recept Signal. 2007;5:e012.
2. Whaley-Connell A, Johnson MS, Sowers JR. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis. 2010;52(5): 401-409.
3. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121): 840-846.
4. Mosso LM, Carvajal CA, Maiz A, et al. A possible association between primary aldosteronism and a lower β-cell function. J Hypertens. 2007;25: 2125-2130.
5. Fischer E, Adolf C, Pallauf A, et al. Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. J Clin Endocrinol Metab. 2013;98(6): 2513-2520.
6. Guo C, Martinez-Vasquez D, Mendez GP, et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology. 2006;147(11): 5363-5373.
7. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure.NEngl J Med. 1999;341(10): 709-717.
8. Luther JM, Luo P, Kreger MT, et al. Aldosterone decreases glucosestimulated insulin secretion in vivo in mice and in murine islets. Diabetologia. 2011;54(8): 2152-2163.
9. Haber CA, Lam TK, Yu Z, et al. N-acetylcysteine and taurine prevent hyperglycemia-induced insulin resistance in vivo: possible role of oxidative stress. Am J Physiol Endocrinol Metab. 2003;285(4): E744-E753.
10. Song D, Hutchings S, Pang CC. Chronic N-acetylcysteine prevents fructose-induced insulin resistance and hypertension in rats. Eur J Pharmacol. 2005;508(1): 205-210.
11. Lautt WW, Schafer J, Macedo MP, Legare DJ. Bethanechol and N-acetylcysteine mimic feeding signals and reverse insulin resistance in fasted and sucrose-induced diabetic rats. Can J Physiol Pharmacol. 2011;89(2): 135-142.
12. Homma T, Fujisawa M, Arai K, Ishii M, Sada T, Ikeda M. Spironolactone, but not eplerenone, impairs glucose tolerance in a rat model of metabolic syndrome. J Vet Med Sci. 2012;74(8): 1015-1022.
13. Park YM, Park MY, Suh YL, Park JB. NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. Biochem Biophys Res Commun. 2004; 313(3): 812-817.
14. Oprescu AI, Bikopoulos G, Naassan A, et al. Free fatty acidinduced reduction in glucose-stimulated insulin secretion: evidence for a role of oxidative stress in vitro and in vivo. Diabetes. 2007;56(12): 2927-37.
15. King H, Aubert RE, HermanWH.Global burden of diabetes, 1995- 2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9): 1414-1431.
16. Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care. 2007;30(9): 2349-2354.
17. Krug AW, Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension. 2008;51: 1252-1258.
18. Gros R, Ding Q, Sklar LA, et al. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension. 2011;57(3): 442-451.
19. Sherajee SJ, Fujita Y, Rafiq K, et al. Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor. Arterioscler Thromb Vasc Biol. 2012;32(2): 257-263.
20. Nuno DW, Harrod JS, Lamping KG. Sex-dependent differences in Rho activation contribute to contractile dysfunction in type 2 diabetic mice. Am J Physiol Heart Circ Physiol. 2009;297(4):H1469-H1477.
21. Lastra G, Whaley-Connell A, Manrique C, et al. Low-dose spirono-lactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG- (mRen2)27 rat. Am J Physiol Endocrinol Metab. 2008;295(1): E110-E116.
22. Salyer SA, Parks J, Barati MT, et al. Aldosterone regulates Na+, K+ ATPase activity in human renal proximal tubule cells through mineralocorticoid receptor. Biochim Biophys Acta. 2013;1833: 2143-2152.
23. Shimizu MH, Coimbra TM, de Araujo M, Menezes LF, Seguro AC. N-acetylcysteine attenuates the progression of chronic renal failure. Kidney Int. 2005;68(5): 2208-2217.
24. He FJ, MacGregor G. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev. 2004;(3):CD004937.
25. Stolarz-Skrzypek K, Kuznetsova T, Thijs L, et al. Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA. 2011;305(17): 1777-1785.
26. Thomas HE, McKenzie MD, Angstetra E, Campbell PD, Kay TW. β-Cell apoptosis in diabetes. Apoptosis. 2009;14(12): 1389-1404.
27. De Angelis N, Fiordaliso F, Latini R, et al. Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat. J Mol Cell Cardiol. 2002;34(12): 1655-1665.
28. Patni H, Mathew JT, Luan L, Franki N, Chander PN, Singhal PC. Aldosterone promotes proximal tubular cell apoptosis: role of oxidative stress. Am J Physiol Renal Physiol. 2007;293(4):F1065-F1071.
29. Mathew JT, Patni H, Chaudhary AN, et al. Aldosterone induces mesangial cell apoptosis both in vivo and in vitro. Am J Physiol Renal Physiol. 2008;295(1):F73-F81.
30. Lee SH, Yoo TH, Nam BY, et al. Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions. Am J Physiol Renal Physiol. 2009;297(5):F1381-F1390.
31. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes. 2003;52(1): 1-8.
32. Drews G, Krippeit-Drews P, Düfer M. Oxidative stress and β-cell dysfunction. Pflugers Arch. 2010;460(4): 703-718.
33. Nishiyama A, Yao L, Nagai Y, et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension. 2004;43(4): 841-848.
34. Tiedge M, Lortz S, Drinkgern J, Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes. 1997;46(11): 1733-1742.
35. Kaneto H, Kajimoto Y, Miyagawa J, et al. Beneficial effects of antioxidants in diabetes: possible protection of pancreatic β-cells against glucose toxicity. Diabetes. 1999;48(12): 2398-2406.
36. Kaneto H, Fujii J, Myint T, et al. Reducing sugars trigger oxidative modification and apoptosis in pancreatic β-cells by provoking oxidative stress through the glycation reaction. Biochem J. 1996; 320(Pt 3): 855-863.
37. Wang X, Li H, De Leo D, et al. Gene and protein kinase expression profiling of reactive oxygen species-associated lipotoxicity in the pancreatic β-cell line MIN6. Diabetes. 2004;53(1): 129-140.
38. Pessôa BS, Peixoto EB, Papadimitriou A, Lopes de Faria JM, Lopes de Faria JB. Spironolactone improves nephropathy by enhancing glucose-6-phosphate dehydrogenase activity and reducing oxidative stress in diabetic hypertensive rat. J Renin Angiotensin Aldosterone Syst. 2012;13(1): 56-66.